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In the current issue of Lancet Psychiatry, Lennox and colleagues present a report in 
which 228 patients with a first episode of psychosis (FEP) were compared with 105 
matched healthy control individuals in regards to prevalence of serum auto-antibodies 
to neuronal surface antigens.1 Serum anti-NMDA receptor antibodies were specifically 
seen in FEP patients (not in healthy controls) without any clear association to 
phenotypic characteristics of the patients. The results call for large scale longitudinal 
studies.  
 
When looking for biological markers to evaluate a disease, knowledge on the pathology 
and/or pathophysiology makes biomarker discovery easier and increases the interpretability of 
the results generated during the discovery process. In psychiatry, the clear and abundant 
pathology of Alzheimer’s disease has facilitated the development of imaging and fluid 
biomarkers for the disease.2 In regards to schizophrenia and several other central nervous 
system diseases, this has been much harder.  
 
For many years, schizophrenia was regarded a functional disorder with no structural basis. 
However, during more than a century of research, a number of macroscopic brain 
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abnormalities have been established, including ventricular enlargement and decreased cortical 
and hippocampal volumes.3 Imaging studies suggest that these changes are present also in 
drug-naïve first episode of psychosis (FEP) patients,4 suggesting that they are not simply 
downstream of lifelong schizophrenia, which was a common criticism against findings in 
autopsy studies. The structural brain changes are not correlated with Alzheimer’s disease 
pathology,5 and there is no firm evidence of gliosis (a much debated topic some 20 years 
ago).3 No other protein pathologies characteristic of proteopathic neurodegenerative diseases 
have been identified. Instead a number of microscopic changes, including reduced neuropil 
and neuronal size, have been identified.3 Whether these are neurodevelopmental or related to 
altered neuronal network activity is presently unknown. Nevertheless, functional 
neuroimaging in patients with schizophrenia can detect aberrant activity in neuronal circuits 
involving the prefrontal cortex, hippocampus and also some subcortical structures.4  
 
Although functional neuroimaging may be the most tangible biomarker for schizophrenia, we 
should not give up on fluid biomarkers. The synaptic changes in autopsy studies are clear and 
also reflected in the cerebral proteome; for example strongly reduced Rab3a expression in the 
thalamus has been observed in schizophrenia.6 Recent advances in analytical technology have 
made it possible to develop quantitative methods to measure synaptic protein concentrations 
in cerebrospinal fluid (e.g., the dendritic protein neurogranin) that correlate with imaging 
evidence of structural and functional synaptic changes in Alzheimer’s disease.7 Perhaps such 
sensitive tests could generate data that reflect the synaptic pathology in schizophrenia and 
give complementary information to neuroimaging? There is also abundant literature on a 
potential role of microglial activation and neuroinflammation in the pathogenesis of 
schizophrenia;8 processes for which cerebrospinal fluid biomarkers do exist. 
 
There are additional aspects that underscore the need of in depth medical evaluation of 
patients with suspected schizophrenia. Schizophrenia-like psychoses may be the dominating 
presenting symptom of, not only encephalitides, but also other neurological disorders, such as 
temporal lobe epilepsy, neurosyphilis, Wilson’s disease and metachromatic leukodystrophy.3  
 
Lennox et al. have now extended these studies to auto-antibodies in serum.1 The knowledge 
that auto-antibodies against neuronal cell surface receptors and related proteins may cause 
encephalitic syndromes that frequently present with psychosis,9 led Lennox and colleagues to 
hypothesise that (i) such auto-antibodies are overrepresented in the serum of FEP patients 
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without clinical signs of encephalitis and (ii) antibody-positive FEP patients would be 
phenotypically different from antibody-negative patients. Seven out of 228 patients had serum 
auto-antibodies against the NMDA receptor, detected using a live cell-based assay, compared 
to none of the controls, whereas the prevalence of a number of other neuronal surface protein 
antibodies was not significantly different between the two groups.1 Antibody-positive and –
negative patients were largely similar in terms of clinical characteristics and treatment 
response over 6 months, but it should be noted that the numbers for comparison were small.  
 
The study does not tell if the anti-NMDA receptor antibodies are a cause or consequence of 
psychosis but the result of increased prevalence in FEP resonates well with a recent meta-
analysis of the literature,10 and calls for large scale longitudinal studies, as well studies 
examining the specificity and pathogenicity of the antibodies. If causality is demonstrated, a 
new field of immunomodulatory treatment opportunities for a subset of FEP patients may 
have been opened, especially since we know that this form of treatment usually leads to 
remission of antibody-mediated encephalitides.  
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